Bli medlem
Bli medlem

Du är här

2016-03-15

Photocure ASA: Photocure announces grant of patents for Cevira®

Oslo, 15 March 2016
- Photocure (OSE: PHO), a specialty pharmaceutical company with focus on
photodynamic technologies in cancer and dermatology today announces that a
new patent for Cevira has been granted in Europe.

Cevira is one of Photocure's promising pipeline products and is being
developed as a new and innovative breakthrough for the treatment of
precancerous lesions of the cervix. The newly granted patent protects the
Cevira drug, its use and its combination with a drug delivery device, such as
the Cevira device, until 2030.

This new key patent in Photocure's Cevira portfolio complements the company's
proprietary two European patents which protect different aspects of the
Cevira device, and which expire 2029.

Concurrently, the United States Patent and Trademark Office has issued a
Notice of Allowance for Photocure's patent application related to the Cevira
drug. A US patent protecting the Cevira drug in a similar way as the
above-mentioned European patent will issue shortly.

"The approval of this latest European patent and the Notice of Allowance for
the equivalent US application is a key milestone for us in our continued work
to secure the long-term value of Cevira. The new patents further strengthen
Photocure's robust patent portfolio and provide Cevira market exclusivity for
the long-term. Cevira is a key asset for us, with the potential to not only
treat HPV induced cervical high grade disease but also to prevent the
development of cervical cancer, which affects more than 500,000 women
annually",said Kjetil Hestdal, President and CEO of Photocure.

For further information, please contact:

Photocure

President&CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:kh@photocure.no
CFO Erik Dahl
Tel: +47 450 55 000, Email:ed@photocure.no

Notes to editors

About Photocure ASA

Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company
and world leader in photodynamic technology. Based on our unique proprietary
Photocure Technology(TM) platform, Photocure develops and commercializes
highly selective and effective solutions within disease areas with high unmet
medical need, such as bladder cancer, HPV and precancerous cervical lesions,
colorectal cancer and skin conditions. Our aim is to provide solutions which
can improve health outcomes for patients worldwide. Photocure is listed on
the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available
atwww.photocure.com.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Photocure ASA via Globenewswire

HUG#1994139

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.